biotech

Is This Atrial Fibrillation Drug Done For After FDA Vote?

Correvio Pharma Corp. (NASDAQ: CORV) shares were crushed after the firm announced the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) decision for its New ...
Read Full Story »

Why This Cystic Fibrosis Study Is Getting a Big Boost

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares jumped on Wednesday after the firm announced positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808 and ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, November 29. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Will This FDA Decision Set Off These Late-Stage Dermatitis Studies?

Dermira Inc. (NASDAQ: DERM) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lebrikizumab, its treatment being ...
Read Full Story »

Why Fate Therapeutics Is One of ASH’s Biggest Winners

Fate Therapeutics Inc. (NASDAQ: FATE) shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal ...
Read Full Story »

Why These 3 Biotechs More Than Doubled on Monday

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a ...
Read Full Story »

Is the Sage Therapeutics Implosion Overblown?

Sage Therapeutics Inc. (NASDAQ: SAGE) shareholders took a bath on Thursday after results from its late-stage major depressive disorder (MDD) trial came public. Despite shares getting more than halved in ...
Read Full Story »

Thursday’s Biggest Biotech Movers

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff. The biotechnology sector is pushing near all-time highs, and ...
Read Full Story »

Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off

Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia. Specifically, the results come from the ...
Read Full Story »

Are Audentes Shareholders Getting Enough in the Acquisition?

Audentes Therapeutics Inc. (NASDAQ: BOLD) shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just ...
Read Full Story »

How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks. Shares were less than $0.50 apiece in November, and only yesterday shares peaked at ...
Read Full Story »

Why Mixed Results From This Chronic Kidney Disease Study Aren’t That Great

Cara Therapeutics Inc. (NASDAQ: CARA) shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease. Specifically, the results come from ...
Read Full Story »

Why Investors Shouldn’t Sleep on This Narcolepsy Study

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial. Specifically, the results come from the Phase 2 Concert ...
Read Full Story »

Why This Atopic Dermatitis Study Was So Well Received

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004 ...
Read Full Story »

Why This Seizure Treatment Could Be the Next Big Thing

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food ...
Read Full Story »